Biovail Tiazac Manufacturing Change Prompts Discussions With FDA

Biovail is considering a manufacturing change for its hypertension drug Tiazac that would strengthen its claim that the product is covered under a recently-listed patent - but may trigger a decision by FDA that the patent cannot be used to block generic competition.